Abcam, ab275245, Human RXRA knockout HCT116 cell lysate

Size: 1Kit
RXRA KO cell lysate available now. KO validated by Immunocytochemistry, Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
Key facts
Cell type:HCT116,
Species or organism:Human,
Tissue:Colon,
Knockout validation:Immunocytochemistry,Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-RXRA, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Immunocytochemistry, Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Retinoid X Receptor alpha (RXRA) also referred to as NR2B1 is a nuclear receptor with a mass of approximately 55 kDa. RXRA functions as a transcription factor and plays a significant role in regulating gene expression by forming heterodimers with other nuclear receptors. RXRA is expressed in many tissues with notable levels in organs like the liver lungs and kidneys. Its ability to bind DNA sequences known as retinoic acid response elements allows RXRA to regulate diverse physiological processes.
Biological function summary
RXRA serves an important role in metabolic regulation especially in lipid metabolism and glucose homeostasis. It forms heterodimers with partners such as peroxisome proliferator-activated receptors (PPARs) enhancing its capacity to modulate various metabolic pathways. These heterodimers facilitate the transcription of genes that respond to nutritional changes. RXRA also influences immune responses and cell differentiation making it important for maintaining cellular health.
Pathways
RXRA operates within the retinoid signaling and lipid metabolism pathways. Through its interaction with PPARs particularly PPAR-γ and PPAR-α RXRA becomes an integral part of the signaling that controls fatty acid storage and glucose metabolism. These pathways influence cellular function and energy balance impacting the body's overall metabolic status.
RXRA has associations with metabolic diseases such as diabetes and cardiovascular disorders. Dysregulation of RXRA expression or function can disrupt lipid and glucose metabolism leading to insulin resistance and metabolic syndrome. The RXRA-PPAR-γ interaction is essential in these conditions with the pair influencing adipogenesis and inflammatory responses. Understanding and targeting RXRA interactions can provide therapeutic prospects for these metabolic disorders.